Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: Principles of Identification and Management.

The first-in-class proteasome inhibitor bortezomib is a potent anti-myeloma drug that now figures prominently in the management of patients with both newly diagnosed and relapsed multiple myeloma. With current studies evaluating its efficacy as part of conditioning prior to and maintenance therapy following autologous stem cell transplantation, it is likely that its role in the management of the disease will expand further. Peripheral neuropathy was recognized as a toxicity associated with bortezomib at an early point in the clinical development of the agent, and further study has provided considerable insight regarding this issue. It is critical that clinicians recognize and appropriately manage bortezomib-induced PN to optimize care for patients. This chapter focuses on the identification, characterization, and management of bortezomib-induced peripheral neuropathy. [ABSTRACT FROM AUTHOR]